ClinicalTrials.gg
CompletedNCT01254383Updated Feb 1, 2021

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

A Phase 1 interventional study of Sildenafil Tablet and Sildenafil ODT in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Singapore. Open to male participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Erectile Dysfunction by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Erectile Dysfunction · Viatris Inc..

Enrollment
21st of 24
36 · median 196
Started
2010
with 4 others
Phase 1
5 of 27
none open now
Registered
26th of 27
by date

Among the 27 studies in Erectile Dysfunction by Viatris Inc., this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2010, is one of 5 in phase 1, and was the 26th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

None of the 27 studies in Erectile Dysfunction by Viatris Inc. is open now. The open studies under Erectile Dysfunction, anywhere →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Erectile Dysfunction by Viatris Inc. as a file.
02

Study summary

This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties as the conventional tablet of sildenafil.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Bioequivalence Oral Dissolving Tablet
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.

(BMI) of 17.5 to 32.5 kg/m2.

Signed and dated document.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormalities
  • Have baseline orthostatic hypotension
  • Positive drug screen, excessive alcohol and tobacco use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Treatment A

    Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions

    Drug: Sildenafil Tablet

  • Experimental
    Treatment B

    Sildenafil ODT tablet 50 mg, administered without water under fasted conditions

    Drug: Sildenafil ODT

  • Experimental
    Treatment C

    Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.

    Drug: Sildenafil ODT

Interventions

  • Tablet, 50 mg, Single Dose

  • DrugSildenafil ODT

    Orally Disintegrating Tablet, 50 mg, Single Dose

  • DrugSildenafil ODT

    Orally Disintegrating Tablet, 50 mg, Single Dose

06

What researchers measure

Primary outcomes

  1. AUC(0-t) of sildenafil.

    Time frame: Up to 1 month

  2. Cmax of sildenafil.

    Time frame: Up to 1 month

Secondary outcomes

  1. AUC(0-inf) of sildenafil, if data permits.

    Time frame: Up to 1 month

  2. Half-life of sildenafil, if data permits.

    Time frame: Up to 1 month

  3. Tmax of sildenafil.

    Time frame: Up to 1 month

  4. Number of patients with adverse events.

    Time frame: Up to 1 month

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

Publications

  • Damle B, Duczynski G, Jeffers BW, Crownover P, Coupe A, LaBadie RR. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014 Feb 1;36(2):236-44. doi: 10.1016/j.clinthera.2013.12.010. Epub 2014 Jan 18. PubMed 24447534 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2010
First posted
Dec 6, 2010
Start
Dec 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01254383
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Dec 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion